---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-038637"
form_type: "8-K"
ticker: "NXGL"
cik: "0001468929"
company_name: "NEXGEL, INC."
filed_at: "2026-08-17T12:15:29+00:00"
generated_at: "2026-08-17T12:20:23.416358+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# NexGel Q2 2026: revenue $3.69M, net loss $2.87M; BioNX backlog $795K; proxy vote fails

## Summary
- Q2 revenue $3.69M, net loss $2.87M; includes $756,554 BioNX amortization, $273,710 transaction costs, $144,495 SilverSeal recall.
- BioNX Surgical backlog ~$795K due to supply chain; Sequence transferring manufacturing to San Antonio, TX.
- Proxy vote failed to increase authorized shares/reverse split; will resolicit standalone, engaged Alliance Advisors, target late Sept.
- $710K restricted cash from ATW Partners released and returned post-quarter; relationship concluded.
- Launched BioNX Regenerative Eye Health & Aesthetics, led by Shaun Mullen; SilverSeal recall supports hospital launch in August.

## SEC filing metadata
- accession: 0001493152-26-038637
- form_type: 8-K
- ticker: NXGL
- cik: 0001468929
- company_name: NEXGEL, INC.
- filed_at: 2026-08-17T12:15:29+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468929/000149315226038637/0001493152-26-038637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468929/000149315226038637/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-038637
- JSON: https://secwatch.observer/filing/0001493152-26-038637.json
- Plain text: https://secwatch.observer/filing/0001493152-26-038637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.